Country for PR: United Kingdom
Contributor: PR Newswire Europe
Monday, November 23 2020 - 09:00
Creation of a research partnership between Pierre Fabre and Y-Biologics for the development of new immunotherapies based on monoclonal antibodies
DAEJEON, South Korea and CASTRES, France, Nov. 23, 2020 /PRNewswire-AsiaNet/--

The South Korean biotech company Y-Biologics and the French pharmaceutical 
group Pierre Fabre have announced their plans to form a strategic partnership 
in the field of immuno-oncology research. The decision has been acknowledged 
through a letter of intent signed by both parties and will be confirmed in the 
coming months through a detailed agreement. The collaboration is set to run for 
three years, with the possibility of a two-year extension.  

Logo -

Logo -

Y-Biologics, which specializes in the discovery of monoclonal antibodies, and 
the Pierre Fabre group, France's second-largest private pharmaceutical 
laboratory, plan to combine their areas of expertise with the aim of 
identifying and developing novel therapeutic monoclonal antibodies targeting 
key immunosuppressive mechanisms activated within solid tumors. 

It has been shown that key cellular components of the tumor microenvironment 
play an important role in helping the tumor thwart the body's immune response. 
Cancer immunotherapies work by specifically reactivating the immune system so 
that it can destroy the tumor cells. The partnership between Pierre Fabre and 
Y-Biologics aims to provide patients with novel therapies based on the use of 
therapeutic monoclonal antibodies that are capable of reprogramming some cell 
types to stimulate and/or restore the anti-tumoral response exerted by the 
immune system.

Under the terms of this agreement, Y-Biologics will contribute through its 
human antibody display platforms to generate therapeutic and diagnostic 
monoclonal antibodies directed against key molecular targets designated by 
Pierre Fabre. For its part, Pierre Fabre will contribute its expertise in 
immuno-oncology  leveraging the skills of its teams located at the Pierre Fabre 
Immunology Centre (CIPF) in Saint-Julien-en-Genevois (discovery and validation 
of immunosuppressive targets, targeted biotherapies) and at the Pierre Fabre 
R&D Centre on the Oncopole campus in Toulouse (translational medicine, 
pharmacology, toxicology, clinical development).

Young Woo Park, CEO of Y-Biologics, stated : << Utilizing Y-Biologics' human 
antibody display platform, we are extremely pleased to have entered into the 
joint study and optional license agreement for antibody discovery for novel 
immuno-oncology targets proposed by Pierre Fabre. We take great pride in 
enabling Pierre Fabre, an important stakeholder in oncology, to recognize our 
antibody discovery platform and expand our technology globally. Y-Biologics 
hope that the candidates we have discovered can step forward into preclinical 
and clinical stage by Pierre Fabre and we are all very pleased to see that this 
partnership broadens the opportunities for subsequent co-development. We look 
forward to continuing our strong relationship with Pierre Fabre through this 
project. >>

<< Innovation in oncology is one of our strategic priorities, therefore we are 
very excited to partner with Y-Biologics in the discovery and development of 
cutting-edge monoclonal antibodies. The agreement with Y-Biologics is another 
testimony of Pierre Fabre´s commitment to accelerate identification of 
innovative therapies for patients who are refractory or resistant to current 
treatments >> added Jean-Luc Lowinski, Medical Care Business Unit CEO at Pierre 

Under the planned partnership, Pierre Fabre would have the option to acquire 
all rights on the antibodies that will be developed under the collaboration. 
These rights will be subject to payments of discovery fees, milestones and 
royalties to Y-Biologics. 

About Y-Biologics 
Founded in 2007, Y-Biologics is a biotech company focusing on the discovery and 
development of novel antibody therapeutics based on its human antibody library 
"Ymax(R)-ABL" & bispecific antibody platform technology "ALiCE" (Antibody Like 
Cell Engager). 

Based on Ymax(R)-ABL, Y-Biologics currently has developed more than 20 antibody 
candidates in various modalities. With a diversity of 10(11), Ymax(R)-ABL has 
highly competitive quality and quantity leading to higher singularity and 
probability of findings from the proprietary library. 

Following early work in discovery, the novel bispecific platform technology 
ALiCE, allows effective redirection of T cells onto tumor cells and thereby 
specifically kill the tumor cells giving very potent and long-lasting efficacy 
in the treatment of cancer patients. ALiCE has overcome the major drawbacks of 
currently available technologies such as excessive toxicity and low 
developability. Therefore, it has strong potential to further address those 
unmet needs in fields of immuno-oncology. 

While focused on research initially, Y-Biologics recently started conducting 
joint development and investment through strategic alliances and providing 
various collaboration opportunities for global partnering. 
For more information:

About Pierre Fabre 
Pierre Fabre is the second largest dermo-cosmetics laboratory in the world, the 
second largest private French pharmaceutical group, and the market leader in 
France for products sold over the counter in pharmacies. Its portfolio includes 
several global brands and franchises, including Eau Thermale Avene, Klorane, 
Ducray, Rene Furterer, A-Derma, Galenic, Elancyl, Naturactive, Pierre Fabre 
Health Care, Pierre Fabre Oral Care, Pierre Fabre Dermatologie and Pierre Fabre 

In 2019, Pierre Fabre generated 2.4 billion euros in revenues, of which 
two-thirds originated from its international business. 
Pierre Fabre, which has always been headquartered in the South-West of France, 
employs approximately 10,500 people worldwide, owns subsidiaries and offices in 
45 countries and enjoys distribution agreements in over 130 countries. 
Pierre Fabre is 86%-owned by the Pierre Fabre Foundation, a 
government-recognized public-interest foundation, and secondarily by its own 
employees through an international employee stock ownership plan. 

In 2019, Ecocert Environment assessed the Group's corporate social and 
environmental responsibility approach according to the ISO 26000 standard on 
sustainable development and awarded it the ECOCERT 26000 "Excellence" level. 
For more information : 

About CIPF (Center of Immunology Pierre Fabre) 
A center of excellence in the area of biotechnologies, the Center of Immunology 
Pierre Fabre (CIPF) develops research programs in the area of cancer 
immunotherapy, with a focus on monoclonal antibodies for therapeutic purposes. 
The departments of Research and Industrial Biotechnology pool their specific 
expertise and know-how to identify antibodies, define their therapeutic 
properties and produce them on the industrial scale.

Contact: Pierre Fabre: 
         Anne Kerveillant, Communication -;
         Y Biologics: 
         Dong-Ock Chang,  

SOURCE:  Pierre Fabre and Y-Biologics